Literature DB >> 35814350

Prognosis of Ischemic Stroke Patients Undergoing Endovascular Thrombectomy is Influenced by Systemic Inflammatory Index Through Malignant Brain Edema.

Yachen Ji1, Xiangjun Xu1, Kangfei Wu1, Yi Sun1, Hao Wang1, Yapeng Guo1, Ke Yang1, Junfeng Xu1, Qian Yang1, Xianjun Huang1, Zhiming Zhou1.   

Abstract

Purpose: The systemic immune inflammatory index (SII), as a new marker, is widely used to predict the disease prognosis. We investigated the predictive value of SII for malignant cerebral edema (MCE) and whether postoperative MCE mediates the relationship between SII and functional prognosis in patients undergoing endovascular thrombectomy (EVT). Patients and
Methods: A total of 829 patients with anterior circulation large-vessel occlusive stroke (LVOS) were registered, and 675 (81.4%) met the inclusion criteria. We collected baseline data upon admission, including SII. Postoperative computed tomography was performed to assess the presence and grading of cerebral edema (CED), and MCE was defined as a CED score of 3. A good prognosis was defined as a modified Rankin Scale (mRS) score of 0-2 at the 90-day follow-up.
Results: A total of 132 patients developed MCE after EVT. The patients were divided into MCE and non-MCE groups, and univariate and multifactorial analyses were performed. Among these risk factors, an elevated SII was independently correlated with the occurrence of MCE. In addition, the receiver operating characteristic (ROC) curve was used to assess the predictive capability of SII levels for prognosis. The area under the ROC was 0.69, and the optimal critical value was 2.14. In addition, postoperative MCE may partially account for the poorer functional prognosis of patients with elevated SII (regression coefficient changed by 40.3%).
Conclusion: The SII is an independent predictor of malignant brain edema after EVT. Postoperative MCE is partly the reason for the poorer prognosis in patients with elevated SII.
© 2022 Ji et al.

Entities:  

Keywords:  acute ischemic stroke; endovascular treatment; malignant cerebral edema; systemic immune inflammatory index

Mesh:

Year:  2022        PMID: 35814350      PMCID: PMC9259057          DOI: 10.2147/CIA.S365553

Source DB:  PubMed          Journal:  Clin Interv Aging        ISSN: 1176-9092            Impact factor:   3.829


Introduction

In recent years, endovascular thrombectomy (EVT) has become the mainstay treatment for large-vessel occlusion stroke (LVOS).1 However, the overall outcome is limited, with only 30–50% of patients having a good prognosis.2 Postoperative malignant cerebral edema (MCE) is a catastrophic complication that can lead to rapid neurological deterioration, midline shift, brain herniation, and death.3 Although there are limited therapeutic approaches to treating MCE, early decompressive hemicraniectomy may potentially reduce mortality and improve the opportunity for good functional outcomes.4 Therefore, early prediction of MCE may be beneficial for patients after EVT. Inflammation is intimately linked to the pathogenesis of stroke.5 Ischemia induces a local immune response and inflammatory factor production, thereby disrupting the tight junctions of the blood-brain barrier (BBB).6 Previous studies have shown that leukocytosis, thrombocytosis and platelet activation are associated with aggravated injury and disruption of the BBB following ischemic stroke.6,7 Based on these studies, the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and lymphocyte-to-monocyte ratio (LMR) have become widely used in the prediction of poor prognosis and complications in ischemic stroke.8–12 And Chen et al reported that the combination of both NLR and PLR had a better predictive value than either alone for predicting poor prognosis following ischemic stroke.13 However, few studies have examined the association between malignant brain edema and inflammation. The systemic immune inflammatory index (SII) is calculated as platelets ×neutrophils/lymphocytes based on cell counts in the peripheral blood.14 Previous studies have reported that the SII is associated with the severity of ischemic stroke;15 in addition, the SII can predict hemorrhagic transformation after ischemic stroke.16 Considering that MCE is thought to share inflammatory and BBB catabolic pathways with cerebral hemorrhage, a similar association may exist between SII and MCE, which deserves further elucidation. Thus, we hypothesized that elevated SII index at admission predicted the development of MCE caused by anterior circulation LVOS in EVT-treated patient. We further explored the relationship between elevated SII and poor prognosis at 90 follow-up, and to investigate the role of postoperative MCE as a mediator between elevated SII and poor prognosis by mediating effect analysis.

Patients and Methods

Patients Selection

In this retrospective study, we included 675 patients with anterior circulation LVOS treated with EVT at two comprehensive stroke centers (January 2014 to December 2018 at Jinling Hospital and September 2015 to July 2021 at Yijishan Hospital). The study was approved by the Ethics Committee of the First Affiliated Hospital of Wannan Medical College (201,900,039). All private data of the participants were anonymized and maintained with confidentiality. The inclusion criteria were as follows: (1) age ≥ 18 years old; (2) onset-to-puncture time (OTP) ≤24h; (3) preoperative modified Rankin Scale (mRS) score < 2; and (4) the occlusion site included the internal carotid artery (ICA) or M1 segment of the middle cerebral artery. The exclusion criteria were as follows: (1) multiple vessel occlusion (MVO) or anterior cerebral artery (ACA) occlusion or M2 segment of the middle cerebral artery occlusion; (2) missing neutrophil, lymphocyte or platelet counts; (3) absence of postoperative imaging data; (4) unavailability of outcome data; and (5) failed edema assessment because of massive cerebral hemorrhage after EVT. A flowchart for inclusion in the study cohort is shown in Figure 1.
Figure 1

Flow chart of the inclusion of the study population.

Flow chart of the inclusion of the study population.

Variable Definition

Prospective registry demographics included age, sex, medical history, and vascular risk factors. We also collected the clinical characteristics of patients, including stroke severity as assessed using the National Institutes of Health Stroke Scale (NIHSS) score and stroke subtype as classified by the Org10172 trial of acute stroke treatment(TOAST).17 The surgical staff recorded procedural variables, including onset-to-puncture time (OTP), site of the occluded vessel, status of cerebral collateral circulation, onset-to-reperfusion time (OTR), and degree of revascularization. Successful recanalization was defined as a Thrombolysis in Cerebral Infarction (mTICI) score of 2b or 3.18 Collateral circulation was evaluated using retrograde angiography of the vessels in the occluded area on digital subtraction angiography (DSA) images prior to reperfusion therapy. Grade 0 collateral circulation was defined as no obvious reconstruction area of collateral blood flow or occluded vessels less than one-third of collateral vessels; grade 1 collateral circulation was defined as collateral blood flow less than two-thirds and more than one-third of the occluded vessel area, and grade 2 collateral circulation was defined as collateral blood flow more than two-thirds of the occluded vessel area or proximal to the main trunk.19,20 Blood samples were collected in tubes containing ethylenediaminetetraacetic acid after reperfusion therapy and within the first 24h after admission. We further collected laboratory data, including the total white blood cell count, neutrophil count (NC), lymphocyte count (LC), and platelet count (PLT). The SII index was calculated using the following formula: SII = [(PLT × NC/LC)/1000]. Cerebral edema (CED) was classified as focal brain swelling up to 1/3 (CED-1) or greater than 1/3 (CED-2) of the hemisphere, or midline shift (CED-3).21 Malignant cerebral edema was defined as CED-3 according to the follow-up images obtained 3–5 days after EVT. A score of 0–2 was defined as a good prognosis based on the 90-d mRS score at outpatient or telephone follow-up.

Statistical Analysis

We grouped patients based on the presence or absence of MCE or favorable and adverse outcomes. Categorical variables are expressed as percentages. Normally distributed continuous variables are summarized as mean ± SD, and non-normally distributed continuous variables are expressed as median and interquartile range (IQR). Nominal variables were compared using the Fisher’s exact test or Pearson’s chi-squared test, and comparisons of continuous variables were made using the Mann–Whitney U-test or Kruskal–Wallis test based on the data distribution. Logistic regression analysis was used to determine predictors of MCE. Variables with P<0.05 in the univariate analysis were included in the multivariate logistic regression model. Receiver operating characteristic (ROC) curves were used to evaluate the ability of the 24-hour postoperative SII index to predict the occurrence of MEC. The optimal test cut-off point was established by calculating Youden’s index. The Sobel test was used for mediation analysis to explore whether postoperative cerebral edema mediated the association between elevated SII (continuous variable) and poor prognosis (90-day mRS score). Statistical significance was set at P<0.05. Statistical analysis was performed using SPSS 26.0 (IBM, Armonk, NY, USA) and data analysis was performed using GraphPadPrism (version 9, La Jolla, CA).

Results

Patient Baseline Characteristics

A series of 829 patients with LVOS were enrolled in these two centers. In total, 154 patients were excluded based on the exclusion criteria and 675 patients were eligible for inclusion in the study. The baseline patient characteristics are shown in Table 1. The mean age of all patients was 67.1 ± 11.4 years; 273 (40.4%) were female. A total of 445 (65.9%) patients had a history of hypertension, 112 (16.6%) had a history of type 2 diabetes, and 327 (48.4%) had a history of atrial fibrillation. The white blood cells count was 10.6 ± 4.1 × 103/μL, neutrophil count was 8.9 ± 3.8 × 103/μL, lymphocyte count was 1.1 ± 0.6 × 103/μL, platelets count was 171.6 ± 60.4 × 103/μL, and SII was 1.75 ± 1.47× 103/μL. The median NIHSS and Alberta Stroke Program Early CT(ASPECT) scores at admission were 15 (12–19) and 9 (7–10), respectively. Of the included patients, 540 (80%) had an mTICI grade of 2b/3.
Table 1

Baseline Clinical Characteristics of the MCE and No MCE Patients

VariablesALL (n=675)No MCE (n=543)MCE (n=132)P
Demographic characteristics
 Age, y, mean (SD)67.1(11.4)66.9(11.5)68.3(11.0)0.171
 Female sex, n (%)273(40.4)216(39.8)57(43.2)0.475
Past Medical History, n (%)
 Hypertension445(65.9)343(63.2)102(77.3)0.002
 Diabetes mellitus112(16.6)86(15.8)26(19.7)0.285
 Atrial fibrillation327(48.4)256(47.1)71(53.8)0.171
Clinical data
 Admission SBP, median (IQR)149(130–161)149(130–161)149(130–163)0.732
 Admission DBP, median (IQR)80(73–90)80(74–90)82(70–91)0.880
 Admission NIHSS, median, (IQR)15(12–19)14(12–18)18(16–21)<0.001
 Admission ASPECT, median, (IQR)9(7–10)9(8–10)7(5–9)<0.001
 IV-rtPA, n (%)129(19.1)98(18.0)31(23.5)0.154
 Occlusion site, n (%)
  ICA312(46.2)218(40.1)94(71.2)<0.001
  MCA-M1363(53.8)325(59.9)38(28.8)
 TOAST type, n (%)
  LAA230(34.1)195(35.9)35(26.5)0.061
  CE368(54.5)284(52.3)84(63.6)
  Others77(11.4)64(11.8)13(9.8)
Procedure process
 OTP, median (IQR)280(220–345)280(220–346)280(223–343)0.999
 OTR,median (IQR)350(286–429)347(283–420)370(313–441)0.036
 Collateral, n (%)
  Grade 0115(17.0)56(10.3)59(44.7)<0.001
  Grade 1232(34.4)179(33.0)53(40.2)
  Grade 2328(48.6)308(56.7)20(15.2)
 mTICI (2b/3), n (%)540(80.0)458(84.3)82(62.1)<0.001
Laboratory data on admission
 FBG, mmol/L,mean (SD)7.2(5.1)6.9(5.3)8.5(3.5)0.001
 Leukocytes, 103/μL, mean (SD)10.6(4.1)10.1(3.4)12.7(5.7)<0.001
 Neutrophils, 103/μL, mean (SD)8.9(3.8)8.3(3.2)11.1(5.3)<0.001
 Lymphocytes, 103/μL, mean (SD)1.1(0.6)1.2(0.6)0.9(0.5)<0.001
 Platelets,103/μL,mean (SD)171.6(60.4)173.0(61.2)165.8(56.7)0.222
 SII index, 103/μ, mean (SD)1.75(1.47)1.57(1.30)2.46(1.86)<0.001
 90d mRS ≤ 2, n (%)325(48.1)313(57.6)12(9.1)<0.001
 90d Death, n(%)141(20.9)59(10.9)82(62.1)<0.001

Abbreviations: MCE, Malignant cerebral edema; SD, standard deviation; IQR, interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; IV-rtPA, intravenous alteplase; TOAST, the Trial of ORG 10172 in Acute Stroke Treatment; LAA, large-artery atherosclerosis; CE, cardioembolic; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; OTP, onset-to-puncture time; OTR, onset-to-reperfusion time; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index; mRS modified Rankin Scale.

Baseline Clinical Characteristics of the MCE and No MCE Patients Abbreviations: MCE, Malignant cerebral edema; SD, standard deviation; IQR, interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; IV-rtPA, intravenous alteplase; TOAST, the Trial of ORG 10172 in Acute Stroke Treatment; LAA, large-artery atherosclerosis; CE, cardioembolic; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; OTP, onset-to-puncture time; OTR, onset-to-reperfusion time; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index; mRS modified Rankin Scale.

Relationship Between SII and MCE in Patients with LVOS

According to the postoperative imaging follow-up, the patients were divided into two groups: the MCE and the non-MCE. Univariate analysis showed that there were significant differences between the two groups in fasting blood glucose (FBG), leukocyte count, neutrophil count, lymphocyte count, SII, history of hypertension, NIHSS score at admission, ASPECT scores at admission, occlusion site, OTR, collateral circulation, rate of recanalization, and 3-month mRS (P<0.05); however, there were no differences between the two groups in age, sex, history of diabetes, atrial fibrillation, systolic or diastolic blood pressure at admission at admission, rate of intravenous alteplase, TOAST type, or OTP (P>0.05, Table 1). Binary logistic regression analysis indicated that after adjustment for NIHSS at admission, ASPECT at admission, collateral circulation, site of occlusion, recanalization status, and FBG level, SII (adjusted odds ratios [OR], 1.209; 95% confidence interval [CI], 1.034–1.413; P=0.017) was independently associated with MCE in the study (Table 2).
Table 2

Multivariate Analysis of Different Variables in MCE Patients

Independent VariableAdjusted OR95% CIP-value
Hypertension1.7430.999–3.0410.050
Admission NIHSS1.0591.012–1.1080.012
Admission ASPECT0.7500.670–0.840<0.001
Collateral
 Grade 0Reference
 Grade10.5240.296–0.9280.027
 Grade20.1750.089–0.345<0.001
Occlusion site
 ICAReference
 MCA-M10.3560.217–0.585<0.001
OTR1.0000.999–1.0020.900
mTICI (2b/3)0.3880.229–0.658<0.001
FBG1.0371.002–1.0740.041
SII1.2091.034–1.4130.017

Abbreviations: OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; OTR, onset-to-reperfusion time; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index.

Multivariate Analysis of Different Variables in MCE Patients Abbreviations: OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; OTR, onset-to-reperfusion time; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index.

SII for Predicting the Development of MCE

Receiver operating characteristic (ROC) analysis was used to determine the ability of the SII to discriminate between patients with LVOS who developed MCE after EVT. An SII of 2.14 was calculated to be the optimal cut-off value to distinguish MCE from non-MCE in patients with LVOS after EVT. The area under the curve was 0.69 (95% CI, 0.66–0.73). An SII value of 2.14 was used as the threshold value to discriminate MCE with a sensitivity and specificity of 0.55 and 0.80, respectively.

Relationship Between SII, Functional Outcome, and MCE

Based on the outcome after 3 months of follow-up, the patients were grouped into two cohorts: 325 (48.1%) were included in the good outcome group (mRS ≤2) and 350 (51.9%) in the adverse outcome group (mRS >2). In the univariate analysis, the percentage of the population with an SII <2.14 was significantly different between those with good and poor prognosis (84.3% vs 61.7% respectively, P<0.001)(Table 3, Figure 2). After adjustment for confounding factors, SII ≥2.14 was associated with a reduced likelihood of functional independence at 90 days (adjusted OR, 3.639; 95% CI, 2.197–6.027; P<0.001, Table 4).
Table 3

Baseline Clinical Characteristics for Different Prognosis

VariablesmRS≤2(n=325)mRS>2 (n=350)P
Demographic characteristics
 Age, y, mean (SD)63.8(11.3)70.2(10.7)<0.001
 Female sex, n (%)105(32.3)168(48.0)<0.001
Past Medical History, n (%)
 Hypertension192(59.1)253(72.3)<0.001
 Diabetes mellitus36(11.1)76(21.7)<0.001
 Atrial fibrillation120(36.9)207(59.1)<0.001
Clinical data
 Admission SBP, median (IQR)146(129–160)150(134–165)0.016
 Admission DBP, median (IQR)80(73–90)80(74–91)0.635
 Admission NIHSS, median, (IQR)14(11–17)17(14–20)<0.001
 Admission ASPECT,median, (IQR)9(8–10)8(7–9)<0.001
 IV-rtPA, n (%)65(20.0)64(18.3)0.571
 Occlusion site, n (%)
  ICA118(36.3)194(55.4)<0.001
  MCA-M1207(63.7)156(44.6)
 TOAST type, n (%)
  LAA134(41.2)96(27.4)<0.001
  CE143(44.0)225(64.3)
  Others48(14.8)29(8.3)
Procedure process
 OTP, median (IQR)284(220–347)270(220–344)0.644
 OTR,median (IQR)347(280–415)355(294–435)0.106
Collateral, n (%)
  Grade 013(4.0)102(29.1)<0.001
  Grade 193(28.6)139(39.7)
  Grade 2219(67.4)109(31.2)
 mTICI (2b/3), n (%)294(90.5)246(70.3)<0.001
Laboratory data on admission
 FBG, mmol/L,mean (SD)6.4(6.1)8.0(3.6)<0.001
 SII <2.14, n (%)274(84.3)216(61.7)<0.001

Abbreviations: mRS, modified Rankin Scale; SD, standard deviation; IQR, interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; IV-rtPA, intravenous alteplase; TOAST, the Trial of ORG 10172 in Acute Stroke Treatment; LAA, large-artery atherosclerosis; CE, cardioembolic; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; OTP, onset-to-puncture time; OTR, onset-to-reperfusion time; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index.

Figure 2

Distribution of modified Rankin Scale (MRS) scores at day 90 according to grouping of SII cutoff values.

Table 4

Multivariate Analysis of Factors Influencing 90-Day Prognosis

Independent VariableAdjusted OR95% CIP-value
Age0.9920.967–1.0180.544
Female:Male1.0680.624–1.8260.811
Hypertension1.9221.063–3.4770.031
Diabetes mellitus0.9470.497–1.8060.869
Atrial fibrillation0.7450.430–1.2930.295
Admission SBP0.9980.988–1.0090.755
Admission NIHSS1.0581.011–1.1070.015
Admission ASPECT0.7500.669–0.840<0.001
Collateral
 Grade 0Reference
 Grade10.4830.265–0.8830.018
 Grade20.1590.079–0.322<0.001
Occlusion site
 ICAReference
 MCA-M10.3620.217–0.604<0.001
mTICI (2b/3)0.3490.201–0.605<0.001
FBG1.0401.002–1.0790.037
SII (≥2.14)3.6392.197–6.027<0.001

Abbreviations: OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index.

Baseline Clinical Characteristics for Different Prognosis Abbreviations: mRS, modified Rankin Scale; SD, standard deviation; IQR, interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; IV-rtPA, intravenous alteplase; TOAST, the Trial of ORG 10172 in Acute Stroke Treatment; LAA, large-artery atherosclerosis; CE, cardioembolic; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; OTP, onset-to-puncture time; OTR, onset-to-reperfusion time; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index. Multivariate Analysis of Factors Influencing 90-Day Prognosis Abbreviations: OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT; ICA, internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; mTICI, modified Thrombolysis in Cerebral Infarction; FBG, fasting blood glucose; SII, systemic immune inflammatory index. Distribution of modified Rankin Scale (MRS) scores at day 90 according to grouping of SII cutoff values. We used mediation analysis to explore whether the effect of an elevated SII on worse prognosis was partially mediated by MCE. Using postoperative MCE as a mediator, we observed a mediating effect of postoperative on MCE in the effect of the SII on prognosis. The regression coefficient was changed by 40.3% (Figure 3).
Figure 3

Analysis of the mediating effect of postoperative cerebral edema on the relationship between SII and functional outcome.

Analysis of the mediating effect of postoperative cerebral edema on the relationship between SII and functional outcome.

Discussion

In this retrospective study of acute ischemic stroke caused by LVOS treated with EVT, our findings were as follows: (1) higher SII can independently predict MCE after EVT, and the area under the curve for the SII index predicting the development of MCE was 0.69 with an optimal cutoff value of 2.14 (sensitivity of 0.55 and specificity of 0.80); (2) postoperative MCE acts as a mediator and is partly responsible for the poor prognosis of patients with an elevated SII. Increasing evidence suggests that inflammation plays a crucial role in the development of malignant brain edema in ischemic stroke. After an ischemic stroke attack, brain-derived antigens, danger-associated molecular patterns (DAMPs), and inflammatory factors enter the body’s circulation from the injured brain region, triggering a series of pro-inflammatory responses that eventually disrupt the blood-brain barrier, leading to the development of acute and late MCE.22,23 In the leukocyte family, neutrophils first infiltrate ischemic brain tissue from approximately 30 min to several hours, and peak 1–3 days after stroke.24 Neutrophils are an important source of matrix metalloproteinase-9, which can lead to early BBB destruction through the release of pro-inflammatory factors, reactive oxygen species and protein hydrolases acting on tight junction proteins, resulting in vascular-derived water in patients with AIS.25,26 Lymphocytes have a complex and diverse impact, and specific isoforms have been shown to inhibit inflammatory responses and maintain BBB integrity in the pathophysiology of cerebral ischemia.27,28 Furthermore, a decrease in lymphocytes was associated with increased pre-stroke cortisol levels and sympathetic tone, suggesting that an overly intense immune response may exacerbate nerve damage.29 The time course of lymphocyte recruitment to the ischemic brain region remains unclear. Animal model research has shown that there is an initial accumulation of T cells in the area of injury during the first 24 h after stroke onset.30 Although platelets mediate thrombosis and coagulation complications associated with vascular disease, platelet activation can directly drive local and systemic inflammatory responses.31 After ischemia/ reperfusion, platelets promote injury by secreting granules and interacting with leukocytes through mechanisms that include enhanced leukocyte extravasation, oxidative rupture, and microvascular occlusion leading to the “no-reflow” phenomenon.7 In our study, the neutrophil count was higher and the lymphocyte count was lower in the MCE group than in the non-MCE group. Nevertheless, there was no statistically significant difference in platelet count between the two groups. Therefore, these pathological findings support our main finding that the SII can be a robust predictor of post-ischemic MCE. Individual blood parameters may be affected by multiple variables such as rehydration, overhydration, and blood specimen disposal. NLR is mainly indicates inflammatory damage, PLR shows hemostatic and thrombotic effects, and SII provides overall information on inflammation, immunity, hemostasis, and thrombosis.32 Statistical analysis in our study showed that SII remained independently associated with MCE after adjustment for FGB, history of hypertension, NIHSS score at admission, ASPECTS at admission, site of occlusion, OTR, collateral circulation, recanalization, and other factors. We used an SII of 2.14 as the threshold; the rate of a 3-month adverse prognosis was markedly higher in patients with a high SII than in patients with a low SII, which is in accordance with previous studies on aneurysmal subarachnoid hemorrhage.33 Our secondary finding was that the effect of an elevated SII on poor prognosis was partially mediated by MCE. Previously, Yi et al investigated the association between SII and clinical prognosis in endovascular therapy.34 This suggests that an elevated SII is associated with poor prognosis, the process of which has not been explored. Recently, Fonseca et al showed that the systemic inflammatory status at admission influenced the outcome of cerebral hemorrhage by increasing perihematomal edema.35 Considering the similarity in the mechanism of action, the current study further investigated the association between SII and functional outcomes and assessed the mediating role of postoperative MCE on functional outcomes in patients undergoing EVT. Our data show that the SII is a significant predictor of functional outcome and that its role may be caused by postoperative MCE. These results confirm the recent findings,15,36 and further illuminate the potential causes of poor prognosis because of elevated SII. Our study has some limitations. First, as a retrospective study, we did not exclude the effect of tumors and other chronic wasting disease populations on inflammatory indicators in terms of inclusion criteria, nor did we explore the relationship between SII and acute infection. Second, our study only chose SII at 24 hours after admission to predict MCE, which lacks an evaluation of the change in dynamics of SII with the degree of cerebral edema. Moreover, brain edema is also influenced by various factors such as treatment.

Conclusion

In conclusion, higher SII levels may indicate MCE, poor prognosis, and systemic immune dysfunction. SII has strong utility as an available and easily accessible clinical indicator for the prediction of MCE, and may provide a reference for clinical practice.
  36 in total

1.  Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group.

Authors:  R D Henderson; M Eliasziw; A J Fox; P M Rothwell; H J Barnett
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

2.  Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke.

Authors:  Gregory A Christoforidis; Yousef Mohammad; Dimitris Kehagias; Bindu Avutu; Andrew P Slivka
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

3.  A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature.

Authors:  J Carvalho-Tavares; M J Hickey; J Hutchison; J Michaud; I T Sutcliffe; P Kubes
Journal:  Circ Res       Date:  2000-12-08       Impact factor: 17.367

4.  Refining angiographic biomarkers of revascularization: improving outcome prediction after intra-arterial therapy.

Authors:  Albert J Yoo; Claus Z Simonsen; Shyam Prabhakaran; Zeshan A Chaudhry; Mohammad A Issa; Jennifer E Fugate; Italo Linfante; David S Liebeskind; Pooja Khatri; Tudor G Jovin; David F Kallmes; Guilherme Dabus; Osama O Zaidat
Journal:  Stroke       Date:  2013-08-06       Impact factor: 7.914

5.  Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials.

Authors:  Katayoun Vahedi; Jeannette Hofmeijer; Eric Juettler; Eric Vicaut; Bernard George; Ale Algra; G Johan Amelink; Peter Schmiedeck; Stefan Schwab; Peter M Rothwell; Marie-Germaine Bousser; H Bart van der Worp; Werner Hacke
Journal:  Lancet Neurol       Date:  2007-03       Impact factor: 44.182

6.  Harms and benefits of lymphocyte subpopulations in patients with acute stroke.

Authors:  X Urra; A Cervera; N Villamor; A M Planas; A Chamorro
Journal:  Neuroscience       Date:  2008-06-13       Impact factor: 3.590

7.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

8.  DAMP signaling is a key pathway inducing immune modulation after brain injury.

Authors:  Arthur Liesz; Alexander Dalpke; Eva Mracsko; Daniel J Antoine; Stefan Roth; Wei Zhou; Huan Yang; Shin-Young Na; Mustafa Akhisaroglu; Thomas Fleming; Tatjana Eigenbrod; Peter P Nawroth; Kevin J Tracey; Roland Veltkamp
Journal:  J Neurosci       Date:  2015-01-14       Impact factor: 6.167

Review 9.  Inflammation after Ischemic Stroke: The Role of Leukocytes and Glial Cells.

Authors:  Jong Youl Kim; Joohyun Park; Ji Young Chang; Sa-Hyun Kim; Jong Eun Lee
Journal:  Exp Neurobiol       Date:  2016-10-26       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.